BioMarin Pharmaceutical (BMRN) Revenue and Net Income History

Historical revenue, operating income and net income for BioMarin Pharmaceutical (BMRN) over the last 10 years. The current TTM revenue for BioMarin Pharmaceutical as of September 25, 2017 is $1.12B.

Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $16.642B $1.117B
BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.